Our **** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Revenue growth of 27.3% was primarily driven by a structural shift in customer demand toward AI-driven drug discovery (AIDD) and high-throughput protein expression.
Management attributes the record adjusted net profit growth of over 200% to improved business quality and operating leverage from long-term investments in automation and digital capacity.
The Life Science Group (LSG) achieved a 29.5% adjusted operating margin, marking a transition from an investment phase to a scale-and-profitability phase.
AI-driven demand is transforming the business model from one-off transactional projects to recurring, high-volume data generation partnerships with tech companies and AI-native biotechs.
#Growth #NVIDIA
Revenue growth of 27.3% was primarily driven by a structural shift in customer demand toward AI-driven drug discovery (AIDD) and high-throughput protein expression.
Management attributes the record adjusted net profit growth of over 200% to improved business quality and operating leverage from long-term investments in automation and digital capacity.
The Life Science Group (LSG) achieved a 29.5% adjusted operating margin, marking a transition from an investment phase to a scale-and-profitability phase.
AI-driven demand is transforming the business model from one-off transactional projects to recurring, high-volume data generation partnerships with tech companies and AI-native biotechs.
#Growth #NVIDIA
29 days ago
